Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05518539 · ClinicalTrials.gov registry record

Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens

A clinical trial of Cataract, sponsored by Newsom Eye & Laser Center.

Completed
Registry status
30
Enrollment target
1
Study location

NCT05518539: Completed study of Cataract, sponsored by Newsom Eye & Laser Center.

NCT05518539 is a study of Cataract that has completed, run by Newsom Eye & Laser Center. The registered enrollment target is 30 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05518539, a study of Cataract, has completed, sponsored by Newsom Eye & Laser Center.

COMPLETED
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

To evaluate visual outcomes and quality of vision following bilateral implantation of the Clareon PanOptix intraocular lens (IOL) targeted for emmetropia.

Conditions Studied

Interventions

  • DEVICE The Clareon™ PanOptix™ Trifocal (toric and non-toric models)

Study Locations (1)

Florida

  • Newsom Eye & Laser Center - Sebring

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-09-08
Est. Completion 2024-06-14
Newsom Eye & Laser Center

2 total trials

What the finished NCT05518539 record still lists

NCT05518539 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which The Clareon™ PanOptix™ Trifocal (toric and non-toric models) is the first listed.

NCT05518539 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05518539 about?

NCT05518539 is a clinical study titled "Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens". To evaluate visual outcomes and quality of vision following bilateral implantation of the Clareon PanOptix intraocular lens (IOL) targeted for emmetropia.

What is the current status of trial NCT05518539?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2022-09-08. Estimated completion is 2024-06-14.

What conditions does trial NCT05518539 study?

This clinical trial studies the following conditions: Cataract.

What interventions are being tested in trial NCT05518539?

The interventions under investigation include: The Clareon™ PanOptix™ Trifocal (toric and non-toric models) (DEVICE).

Who is sponsoring clinical trial NCT05518539?

This trial is sponsored by Newsom Eye & Laser Center, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05518539 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05518539's enrollment target sits among peer trials

30 73rd of 83 higher than 9 of 83 other Cataract trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05518539, the US trial registry maintained by the National Library of Medicine. NCT05518539 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.